User: Guest  Login
Document type:
Clinical Trial; Journal Article
Author(s):
Warm, M; Kates, R; Dick, M; Thomas, A; Mallmann, P; Hoopmann, M; Harbeck, N
Title:
Optimized pro-active management of anemia by Epoetin alpha in pre-operative chemotherapy for primary breast cancer.
Abstract:
This prospective study quantifies the response of hemoglobin and other blood factors to Epoetin alpha (EPO) administration in the course of pre-operative chemotherapy in breast cancer. Blood count time series were analyzed in 38 primary breast cancer patients with/without EPO during the course of pre-operative chemotherapy with epirubicin and paclitaxel. EPO injections improved blood counts in 'anemic' patients (< or =12.0 g/dl) receiving chemotherapy, but had little effect when administered to patients with higher hemoglobin concentrations. On the average, without chemotherapy, hemoglobin concentrations drifted toward about 11.1 g/dl without EPO but could be maintained at near 12.0 g/dl with EPO. In conclusion, there is potential for improved anemia management using EPO during pre-operative chemotherapy, which not only benefits quality of life but could also influence long-term survival in breast cancer through improved tumor oxygenation.
Journal title abbreviation:
Oncol Rep
Year:
2009
Journal volume:
21
Journal issue:
3
Pages contribution:
777-85
Language:
eng
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/19212639
Print-ISSN:
1021-335X
TUM Institution:
Frauenklinik und Poliklinik
 BibTeX